Insight journal, Insight journal - Company

Abbvie: Partnering activity 2009-2014

Posted on 07 July 2014

Tags: , , ,

Abbvie, a top global biopharmaceutical company headquartered in the United States, focusses on solving threatening health problems. A recently formed company in 2013, Abbvie was formed as a separate research based pharma company from Abbott.

Abbvie partners to create drug discovery innovations and to make the most significant impact with the partnership. The company’s partnering activity is reviewed in the article.

The following figure shows the level of Abbvie partnering deal announcements since 2009.

Figure 1: Abbvie partnering deals 2011-2014

Figure 1: Abbvie partnering deals 2011-2014

Figure 1: Abbvie partnering deals 2011-2014

Source: Current Agreements, 2014

Having been recently formed, Abbvie has embarked upon some important partnerships for antibodies and small molecules with companies like Alvine Pharmaceuticals, Galapagos, Ablynx etc. In 2012, Abbot and Abbvie entered into several agreements related to the creation of the research based pharmaceutical.

Analysis of the partnering deals shows a strong emphasis on partnerships in immunology and gastrointestinal and infectious diseases. The company specifically works on immunological diseases like allergy and systemic lupus erythematosus.

The following table provides an overview of the partnering deals announced by Abbvie based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal.

Report: Partnering Agreements with Abbvie 2009-2014                        

Figure 2: Abbvie partnering deals by therapy area 2009-2014

Figure 2: Abbvie partnering deals by therapy area 2009-2014

Figure 2: Abbvie partnering deals by therapy area 2009-2014

Source: Current Agreements, 2014

Further analysis of these deals shows that Abbvie has a preference for licensing and co-promotion deals, similar to many other top pharmaceutical or big biotech companies. Such partnering deals provide the right for Abbvie to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments.

 

The following table provides an overview of the partnering deals announced by Abbvie based on deal type disclosed. 

Figure 3: Abbvie partnering deals by deal type 2009-2014

Figure 3: Abbvie partnering deals by deal type 2009-2014

Figure 3: Abbvie partnering deals by deal type 2009-2014

Source: Current Agreements, 2014

When looking at stage of development at partnering deal signing, the most popular stage at signing is research with 5 deal announcements, followed closely by phase II stage deal announcements. Abbvie has a number of products in their development pipeline mostly in the phase II clinical trial along with multiple programs underway in phase III.

The following table provides an overview of the partnering deals announced by Abbvie based on stage of development at signature.

Figure 4: Abbvie partnering by stage of development 2009-2014

Figure 4: Abbvie partnering by stage of development 2009-2014

Figure 4: Abbvie partnering by stage of development 2009-2014

Source: Current Agreements, 2014

Unsprisingly, like any other big pharma company, Abbvie has entered into some high value deals with companies like Galapagos for the compound GLPG0634 in the treatment of rheumatoid arthritis and Ablynx for nanobodies in SLE treatment.

Figure 5: Top Abbvie partnering deals by headline value 2009-2014

Figure 5: Top Abbvie partnering deals by headline value 2009-2014

Figure 5: Top Abbvie partnering deals by headline value 2009-2014

Source: Current Agreements, 2014

Our report provides more detailed insight into the details of each deal. See: Report: Partnering Agreements with Abbvie 2009-2014

Abbvie partnering at Current Agreements

View all partnering deals for Abbvie: 2014 | 2013 | 2012 | 2011

Full details on each deal can be found at Current Agreements (subscription required)

More 

Summary profile data for Abbvie

Partnering interests for Abbvie

M&A activity for Abbvie

 

Available reports from Current Partnering

Report: Partnering Agreements with Abbvie 2009-2014

Report: Top 50 Big Pharma Partnering and M&A Deal Trends     

 

Available resources for deal coverage for Abbvie          

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Abbvie company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

 

Print Friendly, PDF & Email

Leave a Reply